GRFS Stock Analysis: Buy, Sell, or Hold?
GRFS - Grifois, S.A.
$7.47
-0.16 (-2.10%)
▼
5d:
-7.2%
30d:
-9.23%
90d:
-13.74%
HOLD
MODERATE Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: Jul 29, 2026
Get Alerted When GRFS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: GRFS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: GRFS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$17.72
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$11.00
32.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 6.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GRFS is currently trading at $7.47, which is considered oversold relative to its 30-day fair value range of $7.72 to $8.19. From a valuation perspective, the stock is trading at a discount (Forward PE: 5.2) compared to its historical average (6.3). Remarkably, the market is currently pricing in an annual earnings decline of 6.2% over the next few years. This pessimistic expectation contrasts with the company's recent 43.5% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, GRFS is in a strong downtrend. The price is currently testing key support at $7.42. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GRFS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $10.87 (+45.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GRFS is in a strong downtrend. The price is currently testing key support at $7.42. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GRFS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $10.87 (+45.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$7.72 -
$8.19
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 45.4% below Wall St target ($10.87)
- CAUTION: 5-day price weakness (-7.2%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$7.72 -
$8.19
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$7.43
Resistance Level
$8.24
Current Trend
Strong Downtrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
5.17
Wall Street Target
$10.87
(+45.4%)
Revenue Growth (YoY)
-4.8%
Earnings Growth (YoY)
43.5%
Profit Margin
5.6%
Valuation Discount vs History
-6.2% cheaper
PE vs Historical
5.2 vs 6.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-6.2%
(market-implied from PE analysis)
1-Year Target
$7.01
(-6%)
2-Year Target
$6.57
(-12%)
3-Year Target
$6.16
(-18%)
3-Yr Target (if PE normalizes)
(PE: 5→6)
$7.51
(+1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.9, Growth: 36.0%)
$79.66
(+967%)
Base:
(SPY PE: 5.2, Growth: 36.0%)
$18.80
(+152%)
Bear:
(PE: 4.4, Growth: 36.0%)
$15.98
(+114%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (11x PE), but valuation improves significantly next year (5x PE) as earnings recover.
Trailing PE: 11.34 | Current EPS (TTM): $0.71
Bull Case
$17.71
(+122%)
Analyst growth 100.0%, PE expands to 12.5
Base Case
$16.10
(+102%)
Market implied 100.0%, PE stable at 11.3
Bear Case
$5.47
(-31%)
Severe decline -20.0%, PE contracts to 9.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 5.2 to 6.3
Stabilization Target:
$9.10
(+21.8%)
PE Expansion Potential:
+21.8%
Share & Embed Analysis
Last updated: June 03, 2026 5:37 PM ET
Data refreshes hourly during market hours. Next update: 6:37 PM
Data refreshes hourly during market hours. Next update: 6:37 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GRFS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1211 | 59 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 57 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$253 | 66 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$352 | 65 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$219 | 55 HOLD |
